Claims for Patent: 8,183,203

Summary for Patent: 8,183,203

Title:	Methods for treating pulmonary hypertension and compositions comprising vasoactive intestinal peptide
Abstract:	A method and device for discharging an electrical defibrillation pulse or an electrical demand pacer pulse or delivering at least one pharmaceutical agent to treat conditions such as cardiac arrest, bradycardia, arrhythmia, cardiac standstill, PEA, EMD and other heart conditions are disclosed. The pharmaceutical agent can be delivered into the heart tissue, the heart cavity, or the peritoneal cavity. The pharmaceutical agent can also include analgesics such as morphine. Also included are pharmaceutical agents used to increase myocardial contractility or inhibit platelet aggregation and vasoactive intestinal polypeptide (VIP) and thyroid hormones such as T3 and T4 can be delivered. A method for the treatment of cardiac arrest or pulmonary hypertension patients by administering a therapeutically effective amount of vasoactive intestinal polypeptide is also encompassed by the invention.
Inventor(s):	Rubin; Leo (Suffern, NY)
Assignee:	Avant Garde Therapeutics & Technologies LLC (Suffern, NY)
Application Number:	12/566,908
Patent Claims:	1. A method for treatment of patients with secondary pulmonary hypertension, wherein said secondary pulmonary hypertension is caused by cardiac disease and/or cardiac abnormality or pulmonary disease and/or pulmonary abnormality, and wherein said method comprises: administering a composition comprising an amount of vasoactive intestinal peptide or analogues thereof, or a vasoactive intestinal peptide-like peptide, sufficient to ameliorate at least one symptom of the hypertension. 2. The method according to claim 1, wherein said cardiac disease and or cardiac abnormality is either congenital or acquired. 3. The method according to claim 1, wherein said pulmonary disease and or pulmonary abnormality is either congenital or acquired. 4. The method according to claim 1, wherein the vasoactive intestinal peptide is administered orally. 5. The method according to claim 1, wherein the vasoactive intestinal peptide is administered in an amount between 50 .mu.g and 10 g. 6. The method according to claim 1, wherein the composition comprises vasoactive intestinal peptide at a concentration of between 1 g/ml and 10 g/ml. 7. The method according to claim 1, wherein the composition of vasoactive intestinal peptide comprises other therapeutic substances. 8. The method according to claim 7, wherein said other therapeutic substances are selected from the group consisting of: nifedipine, prostaglandin E, digitalis glycosides, diuretics, secretin, glucagon, norepinephrine, proterenol, histamine, serotonin, and enkephalins. 9. The method according to claim 1, wherein the composition of vasoactive intestinal peptide is sufficient to ameliorate the disease. 10. The method according to claim 9, wherein the vasoactive intestinal peptide is administered by direct injection into a heart cavity of the patient. 11. The method according to claim 10, wherein the vasoactive intestinal peptide is administered via at least one rapid bolus injection. 12. The method according to claim 9, wherein the vasoactive intestinal peptide is administered by parenteral intravenous injection. 13. The method according to claim 12, wherein the vasoactive intestinal peptide is administered into a central venous line of a patient. 14. The method according to claim 12, wherein the vasoactive intestinal peptide is administered via at least one rapid bolus injection. 15. The method according to claim 9, wherein the vasoactive intestinal peptide is administered directly to the pulmonary system of a patient. 16. The method according to claim 15, wherein the vasoactive intestinal peptide is administered by way of direct endotracheal injection. 17. The method according to claim 15, wherein the vasoactive intestinal peptide is administered by way of infusion through the respiratory system of the patient.

Details for Patent 8,183,203

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2019-11-12